Conclusions
This study did not meet its primary efficacy endpoint; it is therefore negative. Overall, however, all efficacy endpoints numerically favored eptinezumab treatment when compared to placebo. In addition, the SUNLIGHT study had similar safety and tolerability compared to previous trials in the overall study population and in the Asian patients, who represented the majority of the population. Moreover, the patient-reported outcome results were aligned with expectations of eptinezumab treatment increasing quality of life. Like previous studies, eptinezumab was proven to be well tolerated in both the placebo-controlled and the open-label period of this study.